These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25642959)

  • 1. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.
    Brat DJ; Cagle PT; Dillon DA; Hattab EM; McLendon RE; Miller MA; Buckner JC;
    Arch Pathol Lab Med; 2015 Sep; 139(9):1087-93. PubMed ID: 25642959
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of tumor markers in central nervous system germ cell tumors by real-time reverse transcriptase polymerase chain reaction using formalin-fixed paraffin-embedded tissues.
    Kim D; Lee DH; Choi J; Shim KW; Kim SH
    Mol Med Rep; 2013 Jan; 7(1):337-41. PubMed ID: 23124437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH mutation status in prostate cancer.
    Ghiam AF; Cairns RA; Thoms J; Dal Pra A; Ahmed O; Meng A; Mak TW; Bristow RG
    Oncogene; 2012 Aug; 31(33):3826. PubMed ID: 22120718
    [No Abstract]   [Full Text] [Related]  

  • 4. Miscellaneous newly recognized types of CNS tumors in the WHO CNS5 classification (other than gliomas, glioneuronal and embryonal tumors).
    Chatterjee D; Gupta K
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S94-S98. PubMed ID: 35562139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Molecular Classification of CNS Malignancies.
    Spino M; Snuderl M
    Adv Anat Pathol; 2020 Jan; 27(1):44-50. PubMed ID: 31714292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Selected biomarkers in the primary tumors of the central nervous system: short review].
    Rychlý B; Grossmann P; Steňo A; Pataky F
    Cesk Patol; 2012 Apr; 48(2):65-71. PubMed ID: 22716052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isochromosome 12p and polysomy 12 in primary central nervous system germ cell tumors: frequency and association with clinicopathologic features.
    Sukov WR; Cheville JC; Giannini C; Carlson AW; Shearer BM; Sinnwell JP; Ketterling RP
    Hum Pathol; 2010 Feb; 41(2):232-8. PubMed ID: 19801160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the molecular genetics of gliomas.
    Nagane M; Huang HJ; Cavenee WK
    Curr Opin Oncol; 1997 May; 9(3):215-22. PubMed ID: 9229142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms.
    Wang J; Bettegowda C
    J Mol Diagn; 2017 Jan; 19(1):24-34. PubMed ID: 27863260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic markers in adult high-grade gliomas.
    Pekmezci M; Perry A
    Semin Radiat Oncol; 2014 Oct; 24(4):235-9. PubMed ID: 25219807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Neuro-Oncology: Time to Go Molecular.
    Becher OJ
    Oncology (Williston Park); 2016 May; 30(5):424-5. PubMed ID: 27188672
    [No Abstract]   [Full Text] [Related]  

  • 12. MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown.
    Braoudaki M; Lambrou GI
    J Hematol Oncol; 2015 Feb; 8():6. PubMed ID: 25652781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutation and protein alteration in 50 gliomas. Retrospective study by DNA-sequencing techniques and immunohistochemistry.
    von Eckardstein K; Gries H; Bolik E; Cervós-Navarro J; Tschairkin IN; Patt S
    Histol Histopathol; 1997 Jul; 12(3):611-6. PubMed ID: 9225141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression.
    Ma K; Chen X; Liu W; Yang Y; Chen S; Sun J; Ma C; Wang T; Yang J
    Sci Rep; 2021 Oct; 11(1):20839. PubMed ID: 34675316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathology of paediatric central nervous system tumours.
    Chiang JC; Ellison DW
    J Pathol; 2017 Jan; 241(2):159-172. PubMed ID: 27701736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma.
    Back M; Rodriguez M; Jayamanne D; Khasraw M; Lee A; Wheeler H
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):556-562. PubMed ID: 29980381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling to analyze embryonal tumors of the central nervous system.
    Packer RJ
    Curr Neurol Neurosci Rep; 2003 Mar; 3(2):117-9. PubMed ID: 12583839
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis.
    Kang Y; Lin X; Kang D
    Medicine (Baltimore); 2020 Aug; 99(33):e21196. PubMed ID: 32871983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics, prognosis and therapy of central nervous system tumors.
    Watkins D; Rouleau GA
    Cancer Detect Prev; 1994; 18(2):139-44. PubMed ID: 8025896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system.
    Adamson DC; Rasheed BA; McLendon RE; Bigner DD
    Cancer Biomark; 2010; 9(1-6):193-210. PubMed ID: 22112477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.